AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors

BACKGROUND. AZD1480 is a novel agent that inhibits Janus-associated kinases 1 and 2 (JAK1 and JAK2). The primary objective of this phase I study was to investigate the safety and tolerability of AZD1480 when administered as monotherapy to patients with solid tumors. METHODS. Thirty-eight patients wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Plimack, Elizabeth R., LoRusso, Patricia M., McCoon, Patricia, Tang, Weifeng, Krebs, Annetta D., Curt, Gregory, Eckhardt, S. Gail
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2013
Schlagworte:
Clinical Trial Results
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3720635/
https://ncbi.nlm.nih.gov/pubmed/23847256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0198
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge